Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Trastuzumab Combined With Pertuzumab and Sequential Use of Pyrotinib vs. Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy

NCT04973319 is registered in ClinicalTrials.gov with Shengjing Hospital as lead sponsor.

NCT NCT04973319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04973319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Trastuzumab Combined With Pertuzumab and Sequential Use of Pyrotinib vs. Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy
Lead sponsor
Shengjing Hospital
Phase
Phase 3
Overall status
Not yet recruiting
Start date
August 1, 2021
Completion date
August 1, 2027
Enrollment
450 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer